Please login to the form below

Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America

Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.
If left untreated, hepatitis C leads to chronic health problems putting a huge strain on national healthcare resources.

During the course of my working life, hepatitis C is one of the therapy areas in which I have seen the most dramatic advances in terms of treatment.  It is definitely one of pharma’s success stories. It has experienced rapid evolution from interferon- and ribavirin-based treatment in 1998, through pegylated interferon-based regimens and protease inhibitors and on to the recent wave of direct-acting antiviral therapies available today. It would not be an exaggeration to say that these interferon-free treatment regimens, with high efficacy (Sustained Virological Response (SVR) rates approaching 100%), minimal side effects and short treatment durations, have the potential to revolutionize the treatment of hepatitis C.

This article considers a more complex reality; how the availability of such exciting new treatments does not necessarily result in a treatment “revolution” in many emerging markets. Specifically, I will explore this in the context of the interesting example of Latin America. 

Read the full article http://www.researchpartnership.com/news/2015/06/breaking-down-the-barriers-to-effective-treatment-of...




25th August 2015

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Rare diseases and orphan drugs: Our experience and expertise

Research Partnership
Conducting research for publication video

Research Partnership
Conference research case study
How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event
Research Partnership
Portfolio analysis: Using market research to master communications across a therapeutic category

Research Partnership
EphMRA round up 2018
EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.
Research Partnership
Patients’willingness to pay
Considerations when developing an appropriate pricing strategy in self-pay markets
Research Partnership